Search Results

Kane Biotech Inc. announces that it has entered into a worldwide license agreement with I-MED Pharma Inc. (“I-MED Pharma” or “I-MED”) for the DispersinB ® technology.

AbSolutions Med, Inc., a privately held medical device company, announced that the Food and Drug Administration has granted Breakthrough Device Designation for its REBUILD Bioabsorbable abdominal wall closure device.

Telehealth company Henry Meds, known for its commitment to patient-centric care, announced the launch of Compounded Oral Dissolving Tirzepatide Tablets.

IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, today announced its PressureSafe™ decision support device has received U.S. Food and Drug Administration (FDA) listing or the indication of pressure injuries.

Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2024 Cell and Gene Meeting on the Med on April 10th at 10:45 AM CET in Rome, Italy.

Kimer Med, a New Zealand-based biotech start-up, announced it has signed a contract valued at up to USD$750,000 with Battelle, the world’s largest independent, nonprofit research and development organisation.

ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2024 Cell and Gene Meeting on the Med, to be held from April 9-11, 2024 in Rome, Italy.

ViroCell Biologics announces that John W. Hadden II, Chief Executive Officer, will be presenting at the annual Cell & Gene Meeting on the Med to be held April 9-11 in Rome, Italy.